ENAP-HL PILLS 20 MG/12.5 MG
ENAP-HL PILLS 20 MG/12.5 MG - 20 TABS
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
- arterial hypertension (in patients for whom combination therapy is indicated).
Dosage and administration
Drug Enap ®-NL 20 should be taken regularly at the same time, preferably in the morning, during or after a meal, without chewing, with a small amount of liquid.
The recommended dose is 1 tab. / Day. If necessary, the dose can be increased to 2 tab., Taken 1 time / day, which is the maximum daily dose.
In patients on diuretic therapy, it is recommended to cancel treatment or reduce the dose of diuretics at least 3 days before the start of treatment with Enap®-NL 20 to prevent the development of symptomatic hypotension.
The duration of treatment is determined by the doctor individually.
In patients with renal failure (CC 30-75 ml / min) Enap therapy®-NL 20 must begin with the appropriate doses of each active substance separately, according to the doses in the combined preparation Enap®-NL 20.
Classification of the incidence of side effects WHO: very often (> 1/10), often (> 1/100 and <1/10), infrequently (> 1/1000 and <1/100), rarely (> 1/10 000 and <1/1000), very rarely (<1/10 000, including individual messages).
From the hemopoietic system: rarely - neutropenia, decreased hemoglobin and hematocrit, thrombocytopenia, leukopenia, inhibition of bone marrow function.
Metabolism: infrequently - gout.
From the side of the central nervous system: very often - dizziness, weakness; often - headache, asthenia; infrequently - insomnia, drowsiness, paresthesia, irritability.
From the senses: infrequently - tinnitus.
Since the cardiovascular system: often - orthostatic hypotension; infrequently - fainting, marked decrease in blood pressure, palpitations, tachycardia, chest pain.
Respiratory: often cough; infrequently - shortness of breath.
Gastrointestinal: often nausea; infrequently - diarrhea, vomiting, dyspepsia, abdominal pain, flatulence, constipation, dryness of the oral mucosa; rarely - cholestatic jaundice, fulminant necrosis of the liver, increased activity of hepatic transaminases and bilirubin; very rarely - intestinal angioedema.
Allergic reactions: infrequently - Stevens-Johnson syndrome; rarely - angioedema.
From the skin: infrequently - skin rash, itching, increased sweating, skin necrosis, alopecia.
From the urinary system: infrequently - impaired renal function, acute renal failure; rarely - an increase in the concentration of urea and creatinine in the serum.
From the reproductive system: infrequently - impotence, decreased libido.
From the musculoskeletal system: often - muscle spasms; infrequently - arthralgia.
From the laboratory indicators: rarely - hyperglycemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia.
Other: a symptom complex has been described, which may include fever, myalgia and arthralgia, serositis, vasculitis, increased ESR, leukocytosis and eosinophilia, skin rash, a positive test for antinuclear antibodies.
- pronounced impaired renal function (CC <30 ml / min);
- angioedema in history, associated with the use of previously ACE inhibitors;
- hereditary or idiopathic angioedema;
- bilateral stenosis of the renal arteries, stenosis of the artery of a single kidney;
- lactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome;
- lactation period;
- children's and teenage age up to 18 years (efficiency and safety are not established);
- hypersensitivity to the drug components or sulfonamide derivatives.
WITH caution the drug should be prescribed for severe stenosis of the aortic mouth or idiopathic hypertrophic subaortic stenosis, coronary artery disease, cerebrovascular diseases (including cerebrovascular insufficiency), chronic heart failure, severe atherosclerosis, severe autoimmune systemic diseases of the connective tissue (including CVM, scleroderma), inhibition of bone marrow hematopoiesis, diabetes mellitus, hyperkalemia, condition after kidney transplantation, impaired liver function, impaired renal function (CC 30-7 5 ml / min), conditions accompanied by a decrease in the BCC (as a result of diuretic therapy, while limiting the consumption of salt, diarrhea and vomiting), elderly patients.
Use during pregnancy and lactation
Drug Enap®-NL 20 is contraindicated during pregnancy.
The effect of ACE inhibitors on the fetus in the first trimester of pregnancy has not been established. The use of ACE inhibitors in the II and III trimesters of pregnancy was accompanied by a negative effect on the fetus and newborn. Newborns developed arterial hypotension, renal failure, hyperkalemia and / or hypoplasia of the skull bones. Perhaps the development of oligohydramnios, apparently due to impaired renal function of the fetus. This can lead to contracture of the limbs, deformation of the bones of the skull, including its facial part, and lung hypoplasia.
The use of diuretics during pregnancy is not recommended, as it can cause fetal and newborn jaundice, thrombocytopenia, and possibly other undesirable reactions observed in adults.
Enalapril and hydrochlorothiazide enter breast milk. Therefore, when prescribing the drug Enap®-NL 20 during lactation must refuse breastfeeding.
Application for violations of the liver
To use the drug with caution in severe violations of the liver.
Application for violations of kidney function
Patients with QA more than 30 ml / min or serum creatinine less than 265 mcmol / L (3 mg / dL) correction dosage is not required.
The drug is contraindicated in anuria, pronounced impaired renal function (CC less than 30 ml / min).
Use in children
Contraindications: children and adolescents under 18 years of age (efficacy and safety have not been established.
Use in elderly patients
WITH caution the drug should be prescribed to elderly patients.
Hypotension with all the clinical consequences can be observed after the first dose of Enap tablets®-NL 20 in patients with severe heart failure and hyponatremia, severe renal insufficiency or left ventricular dysfunction, and in particular in patients with reduced BCC, as a result of diuretic therapy, salt-free diet, diarrhea, vomiting or hemodialysis.
Hypotension that occurred after taking the first dose is not a contraindication for further treatment.
Care must be taken in patients with coronary artery disease, severe cerebrovascular disease, aortic stenosis or idiopathic hypertrophic subaortic stenosis, which prevents the outflow of blood from the left ventricle, severe atherosclerosis, in elderly patients due to the risk of arterial hypotension and deterioration of the heart, brain, and kidneys.
Disorders of water and electrolyte balance
Regular monitoring of the serum electrolyte concentration during the period of treatment is necessary to identify possible imbalances and timely take the necessary measures. The determination of the serum electrolyte concentration is mandatory for patients with prolonged diarrhea, vomiting.
In patients taking the drug Enap®-NL 20, it is necessary to identify signs of impaired water and electrolyte balance, such as dry mouth, thirst, weakness, drowsiness, anxiety, myalgia and cramps (mainly calf muscles), decreased blood pressure, tachycardia, oliguria and gastrointestinal disorders ( nausea, vomiting).
Drug Enap®-NL 20 in patients with renal insufficiency (CK 30-75 ml / min) should be used only after preliminary titration of the doses of Enalapril and hydrochlorothiazide separately, according to the doses in the combined preparation Enap®-NL 20.
Drug Enap®-NL 20 should be used with caution in patients with liver failure or progressive liver disease, because hydrochlorothiazide can cause hepatic coma even with minimal disruption of water and electrolyte balance. It was reported on several cases of acute liver failure with cholestatic jaundice, fulminant necrosis of the liver and fatal outcome (rarely) during treatment with ACE inhibitors. If jaundice occurs and liver transaminases increase, Enap treatment®-NL 20 should be discontinued immediately, patients should be monitored.
Metabolic and endocrine effects
Caution is necessary in all patients receiving treatment with hypoglycemic agents for oral administration or insulin, becausehydrochlorothiazide can weaken, and enalapril strengthen their action.
Thiazide diuretics can reduce Calcium excretion by the kidneys and cause a slight and transient increase in serum calcium levels.
Severe hypercalcemia can be a sign of latent hyperparathyroidism. Before conducting a study of the function of the parathyroid glands, the thiazide diuretics should be canceled.
During treatment with thiazide diuretics, serum levels of cholesterol and triglycerides may increase.
Thiazide diuretic therapy in some patients may exacerbate hyperuricemia and / or aggravate the course of gout. However, enalapril increases the excretion of uric acid by the kidneys, thereby counteracting the hyperuricemic effect of hydrochlorothiazide.
Allergic Reactions / Angioedema
When an angioedema of the face occurs, it is usually sufficient to discontinue the therapy and prescribe an antihistamine to the patient.
Angioedema of the tongue, pharynx, or larynx may be fatal. In case of angioedema of the tongue, pharynx or larynx, which can lead to obstruction of the respiratory tract, it is necessary to immediately administer epinephrine (0.3-0.5 ml of epinephrine (adrenaline) solution in the ratio 1: 1000) and maintain the airway patency (intubation or tracheostomy) .
Among patients of the Negroid race, receiving therapy with an ACE inhibitor, the incidence of angioedema is higher than among patients of a different race.
Patients with a history of angioedema, not associated with ACE inhibitors, have an increased risk of developing angioedema when taking any ACE inhibitor.
In patients taking thiazide diuretics, hypersensitivity reactions may develop with or without allergic reactions. A worsening course of systemic lupus erythematosus has been reported.
Due to the increased risk of Anaphylactic reactions, Enap should not be prescribed.®-NL to 20 patients on hemodialysis using high-flow polyacrylonitrile membranes (AN 69®) undergoing low density lipoprotein apheresis with dextran sulfate and immediately prior to desensitization to wasp or bee venom.
Surgical interventions / general anesthesia
Before surgery (including dentistry), an anesthesiologist should be warned about the use of ACE inhibitors.
During surgical interventions or general anesthesia with the use of agents that cause arterial hypotension, ACE inhibitors can block the formation of angiotensin II in response to compensatory renin release. If this develops a pronounced decrease in blood pressure, explained by a similar mechanism, it can be adjusted by increasing the BCC.
When using ACE inhibitors, cough was noted. The cough is dry, long-lasting, which disappears after stopping the use of ACE inhibitors.In the differential diagnosis of cough, cough caused by the use of ACE inhibitors must also be taken into account.
Influence on ability to drive motor transport and control mechanisms
At the beginning of treatment with Enap®-NL 20 can cause pronounced decrease in blood pressure, dizziness and drowsiness, which can reduce the ability to drive motor vehicles, therefore at the beginning of treatment it is not recommended to drive motor vehicles and engage in other potentially dangerous activities requiring increased concentration and psychomotor reactions.
Symptoms: increased diuresis, marked reduction in blood pressure with bradycardia or other heart rhythm disorders, convulsions, impairment of consciousness (including coma), acute renal failure, impaired acid-base and water-electrolyte balance of the blood.
Treatment: gastric lavage and ingestion of Activated carbon; in more serious cases, transfer the patient to a horizontal position with raised legs, then carry out measures aimed at stabilizing blood pressure - in / in the introduction of plasma substitutes, infusion of a 0.9% sodium chloride solution. The patient should monitor blood pressure, heart rate, respiratory rate, serum concentration of urea, creatinine, electrolytes and diuresis, if necessary, in / in the introduction of angiotensin II, hemodialysis (enalaprilat excretion rate - 62 ml / min).
The use of potassium supplements, potassium-sparing agents or potassium-containing salt substitutes, especially in patients with renal insufficiency, can lead to a significant increase in serum potassium. The loss of potassium during the administration of thiazide diuretics, as a rule, is reduced by the action of enalapril. The content of potassium in the serum usually remains within the normal range.
With simultaneous use with lithium preparations, there is a slowdown in lithium elimination (increased cardiotoxic and neurotoxic effects of lithium).
Thiazide diuretics may enhance the effect of tubocurarine chloride.
The simultaneous use of thiazide diuretics, opioid analgesics or phenothiazine derivatives can lead to orthostatic hypotension.
Combined with enalapril, the use of beta-blockers, alpha-blockers, ganglion-blocking agents, methyldopa or blockers of slow calcium channels can further reduce blood pressure.
The simultaneous use of Allopurinol, cytostatics and immunosuppressants with ACE inhibitors may increase the risk of leukopenia.
Simultaneous administration of thiazide diuretics with GCS and calcitonin can lead to the development of hypokalemia.
Simultaneous use of cyclosporine with ACE inhibitors may increase the risk of hyperkalemia.
The simultaneous use of NSAIDs (including selective COX-2 inhibitors) can weaken the antihypertensive effect of ACE inhibitors.
NSAIDs and ACE inhibitors have an additive effect on the increase in serum potassium, which can lead to a deterioration in renal function, especially in patients with impaired renal function. This effect is reversible.
NSAIDs can reduce the diuretic and antihypertensive effects of diuretics.
Antacids can reduce the bioavailability of ACE inhibitors.
Sympathomimetics can reduce the antihypertensive effect of ACE inhibitors.
Thiazide diuretics can reduce the action of adrenermimetics (epinephrine).
Ethanol enhances the hypotensive effect of ACE inhibitors and thiazide diuretics, which can cause orthostatic hypotension.
Epidemiological studies suggest that the simultaneous use of ACE inhibitors and hypoglycemic agents can lead to hypoglycemia. More often, hypoglycemia develops in the first weeks of therapy in patients with impaired renal function. Long-term and controlled clinical studies of enalapril do not confirm these data and do not limit the use of enalapril in patients with diabetes mellitus. However, such patients should be under regular medical supervision.
The use of hypoglycemic agents for oral administration and insulin with thiazide diuretics may require the correction of their doses.
A single dose of colestyramine or colestipol reduces the absorption of hydrochlorothiazide in the GI tract by 85% and 43%, respectively.
With simultaneous use of ACE inhibitors and gold preparations (sodium aurothiomalate) IV, a symptom complex has been described, including facial flushing, nausea, vomiting, and arterial hypotension.
Terms and conditions of storage
The drug should be stored out of the reach of children at a temperature not higher than 30 ° C.